

Supplementary material for Feltelius N. et al. Utility of registries for post-marketing evaluation of medicines. A survey of Swedish health care quality registries from a regulatory perspective, *Uppsala Journal of Medical Sciences*, 2017

Table. List of publications of potential regulatory significance from registries in the survey, arranged by area of interest

Safety

- A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Holmen C, et al. *A Mult Scler*. 2011;17(6):708-19.
- 5-alpha reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer. Robinson D, et al. *Cancer causes & control*. 2015
- Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. Steineck I, et al. *BMJ*. 2015;350:h3234.
- Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. Raaschou P, et al. *BMJ*. 2013
- Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. Raaschou P, et al. *BMJ*. 2015
- Warfarin-associated intracerebral hemorrhage after ischemic stroke. Åsberg S, et al. *Stroke*. 2014
- Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia. Warnke C, et al. *Neurology*. 2014;83(23):2153-7
- No association between rheumatoid arthritis, amyotrophic lateral sclerosis, and tumour necrosis factor inhibitor treatment. Arkema EV, et al. *Ann Rheum Dis*. 2014;73(11):2061-2.
- Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. O'Farrell S, et al. *J Clin Oncol*. 2015;33(11):1243-51

Effectiveness

- Durability of oral hypoglycemic agents in drug naïve patients with type 2 diabetes: report from the Swedish National Diabetes Register (NDR). Ekström N, et al. *BMJ Open Diabetes Res Care*. 2015
- Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]). Damman P, et al. *Am J Cardiol*. 2014;113(1):64-9.
- Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Glader EL, et al. *Stroke*. 2010;41(2):397-401.
- Antithrombotic Treatment Following Intracerebral Hemorrhage in Patients With and Without Atrial Fibrillation. Pennert J, et al. *Stroke*. 2015;46(8):2094-9
- Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis. Frisell T, et al. *Multiple sclerosis*. 2016
- Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: a report from SCAAR. Koutouzis M, et al. *Heart*. 2011
- Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Chatzidionysiou K, et al. *Ann Rheum Dis*. 2014
- Glycemic Control in Type 1 Diabetes and Long-Term Risk of Cardiovascular Events or Death After Coronary Artery Bypass Grafting. Nystrom T, et al. *J Am Coll Cardiol*. 2015;66(5):535-43

Health economics

- How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop? Neovius M, et al. *Ann Rheum Dis*. 2011
- Immediately versus delayed sequential bilateral cataract surgery. An analysis of costs and patient value. Lundström M, et al. *Acta Ophthalmol* 2009
- Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. Eriksson JK, et al. *Ann Rheum Dis*. 2014
- Impact of Socioeconomic Status on Cardiovascular Disease and Mortality in 24,947 Individuals With Type 1 Diabetes. Rawshani A, et al. *Diabetes Care*. 2015

Methodology

- Incidence of rheumatoid arthritis in Sweden: a nationwide population-based assessment of incidence, its determinants, and treatment penetration. Eriksson JK, et al. *Arthritis Care Res (Hoboken)*. 2013
- Ten years with biologics: to whom do data on effectiveness and safety apply? Simard JF, et al. *Rheumatology (Oxford)*. 2011
- The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Jernberg T, et al. *Heart*. 2010
- Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients. Kiadaliri AA, et al. *Health and Quality of Life Outcomes*. 2015
- Risk of invasive melanoma in patients treated with biologics: results from a collaborative project of 11 European biologic registers. Mercer LK et al. *Ann Rheum Dis* 2016.
- Diabetes care--improvement through measurement. Eliasson B, et al. *Diabetes Res Clin Pract*. 2014 Dec;106 Suppl 2:S291-4.
- The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Gudbjörnsdóttir S, et al. *Diabetes Care*. 2003 Apr;26(4):1270-6.